Companies cannot patent specific pieces of DNA, the US Supreme Court declared yesterday in a mixed decision that also affirmed the rights of the $83bn biotechnology industry in synthetic genetic products.
The justices ruled that synthetic DNA – strands of genetic material that have been modified in a lab – could be patented because this process involved some human input.
The court’s decision invalidated the patents that Myriad Genetics, a biotech company based in Utah, had registered on two human genes: BRCA1 and BRCA2.
您已閱讀35%（523字），剩餘65%（963字）包含更多重要資訊，訂閱以繼續探索完整內容，並享受更多專屬服務。